Vitesse Media is registered in England and Wales at 5th Floor, 6 St. Andrew Street, London, EC4A 3AE . Registered number 2607995, VAT Registration number 782 6511 15.

All information on this website is disclosed in accordance with Rule 26 of the London Stock Exchange's rules relating to AIM quoted companies. Last Updated 24th August 2009

Personalised Health Care: From Theory to Practice

Home > Events > Investors > Managed Events

Science Business - Personalised Health Care event: From Theory to Practice

The conference will draw on new research by Science Business on the macroeconomic impact of personalised healthcare across the EU.

Date: 19 January 2012

Venue: Royal College of Physicians, London

The Event

After years of development, personalised health care is starting to move into clinical practice - and patients, healthcare providers and payers could all benefit. This conference highlights:

* Case studies - where, and in for what indications, has it been shown to work already?
* Modeling - What would be the public health impact be if scaled up across the European Union?
* Management - How should health authorities adapt to maximise the benefit and minimise the cost?
* Investment - What companies, large and small, will be first to capitalise on this opportunity?
* International - How can EU coordination, and international collaboration, speed adoption?

The conference will draw on new research by Science|Business on the macroeconomic impact of personalised health care across the EU. It will provide policy input, networking and information-sharing for:

* Public health authorities and payers across the EU

* Biopharma, ICT, diagnostics and device companies, both small and large

* Investors and analysts

Why should you attend?

* Learn how a more comprehensive approach to stratification can radically reduce overall health system costs and improve patient outcomes

* Discover how the EU is adapting to stratified and personal therapies as well as get the inside track on Horizon 2020 funding under the healthy aging mandate

* Hear first hand examples of how telemedicine and real-time monitoring is radically improving adherence and patient outcomes

* Gain a European wide perspective on next generation stratified therapies, as well as learn how many countries and regions are successfully using health information technology to improve healthcare delivery and efficiency

* Find out how stratification, regulation, and the EU's Horizon 2020 will impact your health care investment strategies and portfolio

*Enjoy our early bird rate and save on registration today!*

Preliminary Agenda:

8:30-9:30	Registration
9:30-9:45	Introduction (TBD)
9:45-10:30	Innovation in personalised health care during an era of austerity Alexander von Gabain, Chairman of the Governing Board, European Institute of Technology Sir Richard Thompson, President, Royal College of Physicians Jesper Nørregaard, Research Director, The Danish Institute for Health Services Researc Adam Heathfield, Director Science Policy Europe, Pfizer Matthias Haury, Head of Science Operations, COST Moderator: Richard Hudson, CEO & Editor, Science\|Business
10:30-11:15	The Research Results: Improving the treatment of cardio vascular disease and breast cancer with personalised health care in France, UK & Belgium Walter Van Dyck Associate Professor of Innovation Management, Vlerick Leuven Management School
11:45-12:30	State of the art: Comparing best practices in personalised healthcare Fabien Calvo, Deputy Director General, Director of Research, French National Cancel Institute Robert C. Wells, Head of Biotechnology Unit, SCience & Technology Policy Division, OECD Lukasz Szumowski, Chair, Department of Arrhythmia Institite of Cardiology, Warsaw, Poland Elizabeth Foot, CEO, London Genetics Stephane Berghmans, Head of Unit, Medical Sciences, European Science Foundation Moderator - Duane Schulthesss, Commercial Director, Science\|Business
13:40-14:25	What is the right model for reimbursement that won't kill innovation? Donald Singer, Professor of Clinical Pharmacology & Therapeutics, Warwick University Richard Fitzgerald, Consultant in Clinical Pharmacology, University of Liverpool Erik Tambuyzer, Managing Director Center for Medical Innovation (CMI), Belgium Nick Crabb, Associate Director - Diagnostics Assessment Programme, Centre for Health Technology Evaluation, National Institute for Health & Clinical Excellence Diego Ossa, Director EU Market Access, Novartis Molecular Diagnostics Moderator: Irene Norstedt, Deputy Head of Unit, Personalised Medicine, DG Research and Innovation, European Commission
14:25-15:10	Breakouts: Managing the risk in healthcare IT systems that cost big money Bart De Loore, Vice President New Business & Managing Director, NXP Semiconductor Walter van Dyck, Associate Professor of Innovation Management, Vlerick Leuven Management School Moderator: Emma Palmer Foster, Strategic Communications Consultant, London Genetics & Oxford Capital Partners Battle of the bulge: successful approaches to fighting obesity and chronic disease David Robinson President, Speedo International Carl Johan Sundberg, Head of Unit Bioentrepreneurship, Karolinska Institutet Sudhesh Kumar, Pro Dean of Research, Warwick University Marek Dziubinski, CTO and President, Medicalgorithmics Moderator: Robert C. Wells, Head of Biotechnology Unit, Science and Technology Policy Division, OECD
15:40-16:25	Standardization, data protection and scale: how we manage medical information in an interconnected Europe? John Crawford, Healthcare Industry Leader, IBM Zahid Latif, Head of Healthcare, UK Technology Strategy Board James Peach, Director, Cancer Research UK Peter Peumans, Department director bio-nano electronics, IMEC Carl Johan Sundberg, Head of Unit Bioentrepreneurship, Karolinska Institutet; Vice President, Euroscience Moderator: Richard Hudson, CEO & Editor, Science\|Business
16:25-17:10	Best practices vs the nanny state: Balancing efficacy and freedom of choice Tom Hudson, President, European Cancer Patient Coalition Neil Ebenezer, Head of New & Emerging Technologies, Medicines & Healthcare products Regulatory Agency Irene Norstedt, Deputy Head of Unit, Personalised Medicine, European Commission Jean-Marie Aerts, Associate Professor, Faculty of Bioscience Engineering, KU Leuven Moderator: Duane Schulthess, Commercial Director, Science\|Business
17:10-18:00	Cocktail Reception

Speakers:

Robert C. Wells
Head, Biotechnology Unit, OECD

Ruxandra Draghia-Akli
Director, Directorate Health, DG RTD, European Commission

Fabien Calvo
Deputy General Director, Institut National du Cancer

Bart De Loore
Vice President New Businesses, NXP Semiconductors

Monica Dietl
Director, COST

James Peach
Director of Stratified Medicine, Cancer Research UK

Walter Van Dyck
Associate Professor of Innovation Management, Vlerick Leuven Gent Management School

Alexander von Gabain
Chairman of the EIT Governing Board and Founder of Intercell AG

Rates & Registration:

Please select from one of the following registration options:

Academic Partner - £79.00
Click here to register

BioPartner (sponsors only) - £79.00
Click here to register

Advisor Delegate - £450.00
Click here to register

Standard Delegate - £249.00
Click here to register

Unsure as to which registration category you fall under? Email us.

Accommodation

Main conference accommodation: Melia White House - To book click here

For alternative accommodation, click here.

Contact us:

If you have any queries regarding the event, please contact:

Jenna Parker
Events Manager
Telephone: 020 7250 7043
Email: jenna.parker@vitessemedia.co.uk

Health for All, Care for You Partners

Lunch Sponsor

Event Partners